These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20186038)

  • 1. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus.
    Kim HA; Jeon JY; Yoon JM; Suh CH
    Am J Med Sci; 2010 Apr; 339(4):337-40. PubMed ID: 20186038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β2-microglobulin as a marker of systemic lupus erythematosus activity.
    Żychowska I; Suszek D; Dryglewska M; Majdan M
    Adv Clin Exp Med; 2018 Mar; 27(3):379-382. PubMed ID: 29533541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus.
    Choe JY; Park SH; Kim SK
    Lupus; 2014 Dec; 23(14):1486-93. PubMed ID: 25124677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Serum β2-microglobulin in Egyptian Patients with Systemic Lupus Erythematosus.
    Abd-Elbaky NM; Albeltagy ES; Hammour AE; Ibrahim AS
    Egypt J Immunol; 2019 Jul; 26(2):143-153. PubMed ID: 31926503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-α-enolase antibody combined with β2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients.
    Huang Y; Chen L; Chen K; Huang F; Feng Y; Xu Z; Wang W
    Lupus; 2019 Mar; 28(3):365-370. PubMed ID: 30813870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients.
    Hermansen ML; Hummelshøj L; Lundsgaard D; Hornum L; Keller P; Fleckner J; Fox B; Poulsen LK; Jacobsen S
    Lupus; 2012 Sep; 21(10):1098-104. PubMed ID: 22577117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to C-reactive protein in incomplete lupus and systemic lupus erythematosus.
    Jung JY; Koh BR; Kim HA; Jeon JY; Suh CH
    J Investig Med; 2014 Aug; 62(6):890-3. PubMed ID: 24896736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody.
    Saigal R; Goyal LK; Agrawal A; Mehta A; Mittal P; Yadav RN; Meena PD; Wadhvani D
    J Assoc Physicians India; 2013 Jun; 61(6):372-7. PubMed ID: 24640201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still's disease.
    Wakabayashi K; Inokuma S; Matsubara E; Onishi K; Asashima H; Nakachi S; Hagiwara K
    Clin Rheumatol; 2013 Jul; 32(7):999-1005. PubMed ID: 23504210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans.
    Kim HA; Jeon JY; Choi GS; Sung JM; Kim MJ; Yun JM; Suh CH
    Clin Immunol; 2008 Aug; 128(2):277-83. PubMed ID: 18504161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
    Pradhan VD; Patwardhan MM; Ghosh K
    Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment of serum-mediated phagocytosis of necrotic material by polymorphonuclear leukocytes to diagnose and predict the clinical features of systemic lupus erythematosus: an observational longitudinal study.
    Compagno M; Gullstrand B; Jacobsen S; Eilertsen GØ; Nilsson JÅ; Lood C; Jönsen A; Truedsson L; Sturfelt G; Bengtsson AA
    Arthritis Res Ther; 2016 Feb; 18():44. PubMed ID: 26860519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta 2-Microglobulin and systemic lupus erythematosus.
    Yeung CK; Wong KL; Wong WS; Chan KH
    J Rheumatol; 1986 Dec; 13(6):1053-8. PubMed ID: 3550072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic lupus erythematosus activity and beta two microglobulin levels.
    Skare TL; Ferri K; Santos MA
    Sao Paulo Med J; 2014; 132(4):239-42. PubMed ID: 25055070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
    Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
    Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
    Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus.
    Suleiman S; Kamaliah D; Nadeem A; Naing NN; Che Maraina CH
    Int J Rheum Dis; 2009 Jul; 12(2):100-6. PubMed ID: 20374326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.